Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Medigene AG. (2/26/18). "Press Release: Medigene Announces Participation at Four Upcoming Conferences". Planegg.

Organisations Organisation Medigene AG (MDG1, Frankfurt, Prime Standard)
  Group Medigene (Group)
  Organisation 2 Needham & Company, LLC
  Group Needham (Group)
Products Product BIO-Europe Spring 2018 Amsterdam
  Product 2 T cell therapy
Index terms Index term Medigene–Roth Capital Partners: investor conference, 201803 supply service Medigene presents at Annual Roth Conference 2018
  Index term 2 Medigene–Needham: investor conference, 201803 supply service Medigene presents at Annual Needham Healthcare Conference in NY
Persons Person Taapken, Thomas (Medigene 201701– CFO before Epigenomics + Biotie/elbion + DVC + Burrill + Hoechst)
  Person 2 Mayer, Robert (Medigene 201512– Senior Manager PR + IR before College Hill Life Sciences/Northbank Munich)
     


Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at four upcoming investors, business development and scientific conferences:

Biologics & Biosimilars Congress
Date: 5 - 6 March 2018
Location: Berlin, Germany

Annual ROTH Conference
Date: 11 - 13 March 2018
Location: Orange County, CA, USA
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation for investors on 13 March.

BIO-Europe Spring
Date: 12 - 14 March 2018
Location: Amsterdam, Netherlands

Annual Needham Healthcare Conference
Date: 27 - 28 March 2018
Location: New York, USA
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation on 28 March.


Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com


This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.


Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

   
Record changed: 2018-03-08

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px

More documents for Medigene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px




» top